Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.

Abstract:

:Preclinical studies have indicated that hydroxyurea leads to enhancement of 5-fluorouracil (5-FU) activity when given after 5-FU. This is presumably due to hydroxyurea's actions resulting in maintaining low levels of deoxyuridine monophosphate pools. The combination of hydroxyurea and 5-FU has been tested in several inconclusive clinical trials in patients with advanced colorectal cancer. However, pharmacodynamic studies have been lacking, and the schedules tested have not usually tried to follow preclinical findings. With the current renewed interest in 5-FU, a role for hydroxyurea as part of its biochemical modulation is worthy of further study.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Muggia FM,Moran RG

subject

Has Abstract

pub_date

1992-06-01 00:00:00

pages

90-3

issue

3 Suppl 9

eissn

0093-7754

issn

1532-8708

pii

0093-7754(92)90135-N

journal_volume

19

pub_type

杂志文章,评审
  • Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

    abstract::Malignant biliary obstruction, duodenal, and gastric outlet obstruction, and tumor-related pain are the complications of unresectable pancreatic adenocarcinoma that most frequently require palliative intervention. Surgery involving biliary bypass with or without gastrojejunostomy was once the mainstay of treatment in ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.014

    authors: Stark A,Hines OJ

    更新日期:2015-02-01 00:00:00

  • VP-16 and cisplatin in the treatment of non-small-cell lung cancer.

    abstract::The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Klastersky J

    更新日期:1985-03-01 00:00:00

  • Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

    abstract::Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Synold TW,Tetef ML,Doroshow JH

    更新日期:1998-08-01 00:00:00

  • Spirituality and healing.

    abstract::Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2004.11.017

    authors: Torosian MH,Biddle VR

    更新日期:2005-04-01 00:00:00

  • Pemetrexed in the treatment of non-small cell lung cancer.

    abstract::A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.37470

    authors: Shepherd FA

    更新日期:2002-12-01 00:00:00

  • Prognostic models in melanoma.

    abstract::Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Halpern AC,Schuchter LM

    更新日期:1997-02-01 00:00:00

  • Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).

    abstract::In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-small cell lung cancer (NSCLC). Based on these findings, a phase II tr...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Johnson DH,Paul DM,Hande KR,DeVore R

    更新日期:1996-12-01 00:00:00

  • Pharmacokinetics of paclitaxel and carboplatin in combination.

    abstract::We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a tar...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kearns CM,Belani CP,Erkmen K,Zuhowski M,Hiponia D,Zacharski D,Engstrom C,Ramanathan R,Trenn MR,Aisner J

    更新日期:1995-10-01 00:00:00

  • Gemcitabine combined with docetaxel in metastatic breast cancer.

    abstract::The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2003.37270

    authors: Fumoleau P

    更新日期:2003-04-01 00:00:00

  • Lymphomas of the head and neck.

    abstract::Lymphomas of the head and neck arise in Waldeyer's ring, the salivary glands, nasal cavity, paranasal sinuses, thyroid gland, and orbit. Though anatomically in close proximity, lymphomas arising in these sites have distinct clinical characteristics. Factors that appear to influence the pattern of disease include concu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Yuen A,Jacobs C

    更新日期:1999-06-01 00:00:00

  • Opportunities and challenges in the development of targeted therapies.

    abstract::Expanding knowledge about basic biology and a detailed understanding of the signaling pathways that participate in the growth and metastasis of breast cancer have identified opportunities for diagnostic and therapeutic intervention. Endocrine therapy represents the first and most successful example of targeted therapy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.01.003

    authors: Hortobagyi GN

    更新日期:2004-02-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Chemotherapeutic approaches to advanced breast cancer.

    abstract::Choices of treatment for patients with estrogen receptor (ER) positive metastatic breast cancer refractory to first-line endocrine therapies include progestins, antiadrenal drugs, and androgens. These treatments should be administered sequentially to achieve maximum palliation of the disease. For ER positive patients ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Buzdar AU

    更新日期:1988-06-01 00:00:00

  • Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study.

    abstract::The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for pre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rosenthal DI,Sinard RJ,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Griener J,Frenkel EP,Carbone DP

    更新日期:1997-12-01 00:00:00

  • Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

    更新日期:1995-08-01 00:00:00

  • Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group.

    abstract::Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Loehrer PJ Sr

    更新日期:1992-12-01 00:00:00

  • Transfusion support in acute leukemias.

    abstract::Patients with acute myeloid leukemia and acute lymphocytic leukemia receive significant numbers of blood products for hematologic support during periods of disease and treatment related cytopenias. These patients may be at increased risk for complications associated with transfusion. This article reviews the indicatio...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Webb IJ,Anderson KC

    更新日期:1997-02-01 00:00:00

  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

    abstract::Oxaliplatin, which was recently approved by the US Food and Drug Administration for the treatment of advanced colorectal cancer, is often administered to patients with altered liver function caused by hepatic metastases. Because of the absence of data on the clearance of oxaliplatin in patients with liver dysfunction,...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0093-7754(03)00400-7

    authors: Doroshow JH,Synold TW,Gandara D,Mani S,Remick SC,Mulkerin D,Hamilton A,Sharma S,Ramanathan RK,Lenz HJ,Graham M,Longmate J,Takimoto CH,Ivy P

    更新日期:2003-08-01 00:00:00

  • Intraperitoneal therapy in renal failure.

    abstract::As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

    journal_title:Seminars in oncology

    pub_type: 历史文章,杂志文章

    doi:

    authors: Twardowski ZJ

    更新日期:1985-09-01 00:00:00

  • Epidemiology of acute myelogenous leukemia.

    abstract::The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled ou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sandler DP

    更新日期:1987-12-01 00:00:00

  • Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.

    abstract::Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.10.004

    authors: Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

    更新日期:2016-12-01 00:00:00

  • Current treatment of medulloblastoma: recent advances and future challenges.

    abstract::Medulloblastoma (MB) is the most common malignant brain tumor of childhood, yet it makes up only 1% of adult brain tumors. MB is uniquely sensitive to chemotherapy and radiation, but successful surgical resection continues to be an important component of therapeutic success. Progress in the treatment of MB has occurre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.009

    authors: Rood BR,Macdonald TJ,Packer RJ

    更新日期:2004-10-01 00:00:00

  • Solid tumor second primary neoplasms: who is at risk, what can we do?

    abstract::Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.09.012

    authors: Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

    更新日期:2013-12-01 00:00:00

  • Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas.

    abstract::The results of adjuvant chemotherapy in high-grade gliomas are disappointing. Carmustine (BCNU) wafers placed in the resection cavity provide a modest increase in median survival. However, the overall benefit of this approach is small, it offers no potential for cure, and the results are not statistically significant ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.035

    authors: Grossman SA

    更新日期:2003-12-01 00:00:00

  • Molecular biology of colorectal cancer: new targets.

    abstract::Colorectal cancer is an ideal model in which to study malignant progression from the molecular-genetic perspective because different stages of the same malignancy coexist within each patient. Approximately 75% of colorectal cancer cases are sporadic and the remaining are familial disease, yet genetic mutations that ha...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.003

    authors: Kitisin K,Mishra L

    更新日期:2006-12-01 00:00:00

  • Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.

    abstract::The ability of dexrazoxane (DEX) to protect against doxorubicin (DOX)-induced cardiomyopathy has been demonstrated in mice, normotensive and hypertensive rats, rabbits, dogs, swine, and humans. These animal models of DOX-induced cardiomyopathy were found to be highly predictive of DEX activity clinically. In mice admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Imondi AR

    更新日期:1998-08-01 00:00:00

  • The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.

    abstract::Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • Carcinoma of the uterine cervix: current status and future directions.

    abstract::Based on rigorous interpretation of current evidence, systemic therapy has two roles in the management of carcinoma of the uterine cervix. In patients with advanced or recurrent disease, single-agent chemotherapy constitutes the treatment of choice. The most extensively studied agents are the platinum compounds. Eithe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Thigpen T,Vance RB,Khansur T

    更新日期:1994-04-01 00:00:00

  • Single-agent gemcitabine in non-small cell lung cancer: the French experience.

    abstract::Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Le Chevalier T,Gottfried M

    更新日期:1997-04-01 00:00:00